[HTML][HTML] Efficacy and safety of umeclidinium/vilanterol 62.5/25ámcg and tiotropium 18ámcg in chronic obstructive pulmonary disease: Results of a 24-week …

MR Maleki-Yazdi, T Kaelin, N Richard, M Zvarich… - Respiratory …, 2014 - Elsevier
M. Reza Maleki-Yazdi has acted as a consultant to and received research grants from
Almirall, AstraZeneca, Boehringer Ingelheim, Forest Laboratories, GlaxoSmithKline, Novartis, …

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

D Singh, MR Maleki-Yazdi, L Tombs… - … journal of chronic …, 2016 - Taylor & Francis
Background Minimizing the risk of disease progression and exacerbations is the key goal of
COPD management, as these are well-established indicators of poor COPD prognosis. We …

[HTML][HTML] Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three …

MR Maleki-Yazdi, D Singh, A Anzueto, L Tombs… - Advances in …, 2016 - Springer
Introduction Dual bronchodilator therapy is reserved as a second-line treatment in patients
with chronic obstructive pulmonary disease (COPD) and provides benefits in lung function …

The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada

MR Maleki-Yazdi, SM Kelly, SS Lam, M Marin… - Canadian respiratory …, 2012 - hindawi.com
INTRODUCTION: No recent Canadian studies with physician- and spirometry-confirmed
diagnosis of chronic obstructive pulmonary disease (COPD) that assessed the burden of COPD …

Respiratory rate during acute asthma

S Kesten, MR Maleki-Yazdi, BR Sanders, JA Wells… - Chest, 1990 - Elsevier
Asthmatic patients hyperventilate during acute attacks, but controversy persists as to
whether they breathe rapidly, deeply or both. We monitored respiratory rate under the three …

[HTML][HTML] Dose determination for a fixed-dose drug combination: a phase II randomized controlled trial for tiotropium/olodaterol versus tiotropium in patients with COPD

F Maltais, A Hamilton, F Voß, MR Maleki-Yazdi - Advances in therapy, 2019 - Springer
M. Reza Maleki-Yazdi acted as a consultant and has received research grants form Almirall,
AstraZeneca, Boehringer Ingelheim, Forrest Laboratories, GlaxoSmithKline, Novartis, Merck…

Early detection and impaired quality of life in COPD GOLD stage 0: a pilot study

MR Maleki-Yazdi, CK Lewczuk… - COPD: Journal of …, 2007 - Taylor & Francis
This pilot study aimed to identify early stages of chronic obstructive pulmonary disease (COPD)
in an urban population of smokers and ex-smokers using the Global Initiative for Chronic …

[PDF][PDF] Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD

R Aalbers, MR Maleki-Yazdi, A Hamilton… - Eur Respir …, 2012 - researchgate.net
• The aim of this study was to determine the optimum once-daily dose of olodaterol (5.0 and
10.0 μg) and tiotropium (1.25, 2.5 and 5.0 μg) in combination when delivered via the …

Importance of distinguishing between asthma and chronic obstructive pulmonary disease in primary care

…, D Price, P Kardos, MR Maleki-Yazdi - Canadian Family Physician, 2021 - cfp.ca
… Dr M. Reza Maleki-Yazdi has received speaker’s bureau and honoraria and consultancy
fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Nycomed, Novartis, …

[HTML][HTML] Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic …

R Aalbers, MR Maleki-Yazdi, A Hamilton… - Advances in …, 2015 - Springer
Introduction Combining long-acting muscarinic antagonists (LAMAs) and long-acting β 2 -agonists
(LABAs) is beneficial in chronic obstructive pulmonary disease (COPD), as the two …